news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

[ Sinomed is a leading company in the field of aortic and peripheral vascular intervention in my country. Its independently developed Castor branched stent graft system (hereinafter referred to as "Castor stent") is the world's first branched aortic stent approved for the treatment of aortic arch lesions. The 2023 annual report shows that the Castor stent has covered more than 1,000 terminal hospitals. ]

The factory price of a stent is 50,000 yuan, and the agency price is 120,000 yuan. The price of a product of Xinmai Medical has attracted great attention in the "four soul-searching questions" of the National Medical Insurance Bureau. On the morning of August 20, the day after the National Medical Insurance Bureau issued a public inquiry letter, Xinmai Medical responded quickly that the company is willing to further take the initiative to adjust the price under the guidance of the National Medical Insurance Bureau.

On August 19, the National Healthcare Security Administration stated in a public inquiry letter that the ex-factory price of SinoPac Medical's Castor stent (200mm length) was about 50,000 yuan, and the price supplied to medical institutions by agents exceeded 120,000 yuan. After a preliminary meeting, the company proposed a price adjustment plan, but it did not change the fact that the price difference significantly exceeded the necessary range.

At the opening of the market on the morning of August 20, the share price of Cardiovascular Medical (688016.SH) opened sharply lower by more than 10%, and closed down 13.89% to HK$83.25.

A reporter from China Business News found that this is the third time that Xinmai Medical has been questioned by the regulatory authorities this year. The previous issues involved overseas acquisitions at a high premium and a high concentration of major customers.

The company responded to the four soul-searching questions from the Medical Insurance Bureau